$ESGH
ESG Inc.

2024 Q3 Form 10-Q Financial Statement

#000152013824000421 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2023 Q3
Revenue $2.235M $0.00
YoY Change
Cost Of Revenue $1.726M $101.9K
YoY Change 1594.48%
Gross Profit $508.6K $416.3K
YoY Change 22.15%
Gross Profit Margin 22.76%
Selling, General & Admin $241.9K $20.00K
YoY Change 1109.74%
% of Gross Profit 47.57% 4.8%
Research & Development $144.6K $152.8K
YoY Change -5.4%
% of Gross Profit 28.43% 36.71%
Depreciation & Amortization $444.5K $0.00
YoY Change
% of Gross Profit 87.41% 0.0%
Operating Expenses $386.5K $20.00K
YoY Change 1832.65%
Operating Profit $122.0K -$17.72K
YoY Change -788.64%
Interest Expense $125.4K $0.00
YoY Change
% of Operating Profit 102.74%
Other Income/Expense, Net -$180.00 $29.65K
YoY Change -100.61%
Pretax Income -$3.521K -$20.00K
YoY Change -82.4%
Income Tax $0.00
% Of Pretax Income
Net Earnings $22.70K -$20.00K
YoY Change -213.49%
Net Earnings / Revenue 1.02%
Basic Earnings Per Share $0.01 -$0.01
Diluted Earnings Per Share $0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 25.90M shares 25.90M shares
Diluted Shares Outstanding 25.90M shares 25.90M shares

Balance Sheet

Concept 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.00K
YoY Change -88.89%
Cash & Equivalents $444.8K $6.449K
Short-Term Investments
Other Short-Term Assets $40.00K
YoY Change
Inventory $1.870M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.733M $46.45K
YoY Change 7937.55% -46.08%
LONG-TERM ASSETS
Property, Plant & Equipment $17.95M $769.00
YoY Change 2333932.25% -25.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $23.40M $769.00
YoY Change 3042560.73% -25.27%
TOTAL ASSETS
Total Short-Term Assets $3.733M $46.45K
Total Long-Term Assets $23.40M $769.00
Total Assets $27.13M $47.22K
YoY Change 57359.91% -45.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.731M $1.000K
YoY Change 273046.7% -70.29%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.69M $1.000K
YoY Change 1369023.9% -70.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.69M $1.000K
Total Long-Term Liabilities $0.00
Total Liabilities $15.03M $1.000K
YoY Change 1502506.4% -70.29%
SHAREHOLDERS EQUITY
Retained Earnings -$1.708M -$93.95K
YoY Change 1718.47% 66.68%
Common Stock $25.90K $15.47K
YoY Change 67.45% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.034M $46.22K
YoY Change
Total Liabilities & Shareholders Equity $27.13M $47.22K
YoY Change 57359.91% -45.83%

Cashflow Statement

Concept 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income $22.70K -$20.00K
YoY Change -213.49%
Depreciation, Depletion And Amortization $444.5K $0.00
YoY Change
Cash From Operating Activities -$20.00K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$40.00K
YoY Change
Cash From Investing Activities -$40.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -20.00K
Cash From Investing Activities -40.00K
Cash From Financing Activities 0.000
Net Change In Cash -60.00K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$20.00K
Capital Expenditures $0.00
Free Cash Flow -$20.00K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Liabilities
Liabilities
15026064 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25899468 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25899468 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25899468 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25899468 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
25900 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
25900 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11152388 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11152388 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-435822 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-430206 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1224811 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
9034032 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9523271 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
3071325 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
3274308 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12105357 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12797579 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27131421 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26273652 usd
CY2024Q3 us-gaap Revenues
Revenues
2234549 usd
CY2023Q3 us-gaap Revenues
Revenues
518192 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56532
dei Entity Registrant Name
EntityRegistrantName
ESG INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-1918342
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2023Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
3085906 usd
CY2024Q3 us-gaap Value Added Tax Receivable Noncurrent
ValueAddedTaxReceivableNoncurrent
2380839 usd
CY2023Q4 us-gaap Value Added Tax Receivable Noncurrent
ValueAddedTaxReceivableNoncurrent
2211980 usd
CY2023Q4 ESGH Note Receivable Noncurrent
NoteReceivableNoncurrent
41848 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
23398061 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
24034703 usd
CY2024Q3 us-gaap Assets
Assets
27131421 usd
CY2023Q4 us-gaap Assets
Assets
26273652 usd
CY2024Q3 srt Bank Loans
BankLoans
6939101 usd
CY2023Q4 srt Bank Loans
BankLoans
6904228 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2731467 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1450405 usd
CY2023Q4 ESGH Payable To Related Party Current
PayableToRelatedPartyCurrent
30000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2749583 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2312772 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1271088 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1355552 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13691239 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12052957 usd
CY2024Q3 ESGH Longterm Payable Noncurrent
LongtermPayableNoncurrent
1334825 usd
CY2023Q4 ESGH Longterm Payable Noncurrent
LongtermPayableNoncurrent
1423116 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Revenues
Revenues
5959055 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
1725979 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
101859 usd
us-gaap Cost Of Revenue
CostOfRevenue
6272487 usd
us-gaap Cost Of Revenue
CostOfRevenue
4496465 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
508570 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
416333 usd
us-gaap Gross Profit
GrossProfit
850123 usd
us-gaap Gross Profit
GrossProfit
1462590 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
144582 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
152839 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
404366 usd
us-gaap Selling Expense
SellingExpense
4776 usd
us-gaap Selling Expense
SellingExpense
1863 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
239656 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
279953 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
703078 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
876271 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
122041 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17722 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-262096 usd
us-gaap Interest Expense
InterestExpense
287134 usd
CY2024Q3 ESGH Other Income Loss
OtherIncomeLoss
180 usd
CY2023Q3 ESGH Other Income Loss
OtherIncomeLoss
-29652 usd
ESGH Other Income Loss
OtherIncomeLoss
15605 usd
ESGH Other Income Loss
OtherIncomeLoss
-133180 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3521 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
74483 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-684686 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-3521 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
74483 usd
us-gaap Profit Loss
ProfitLoss
-684686 usd
us-gaap Profit Loss
ProfitLoss
-26804 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-26218 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
28829 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-201063 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
13337 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
22697 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
45654 usd
us-gaap Net Income Loss
NetIncomeLoss
-483623 usd
us-gaap Net Income Loss
NetIncomeLoss
-40141 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
161997 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-191087 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5616 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToNoncontrollingInterest
-55390 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToNoncontrollingInterest
65336 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToNoncontrollingInterest
1920 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToNoncontrollingInterest
192165 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
29173 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-36507 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-202983 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-602152 usd
CY2024Q3 ESGH Total Comprehensive Income Attributable To Shareholders Of Esg Inc.
TotalComprehensiveIncomeAttributableToShareholdersOfEsgInc.
-184693 usd
CY2023Q3 ESGH Total Comprehensive Income Attributable To Shareholders Of Esg Inc.
TotalComprehensiveIncomeAttributableToShareholdersOfEsgInc.
145433 usd
ESGH Total Comprehensive Income Attributable To Shareholders Of Esg Inc.
TotalComprehensiveIncomeAttributableToShareholdersOfEsgInc.
489239 usd
ESGH Total Comprehensive Income Attributable To Shareholders Of Esg Inc.
TotalComprehensiveIncomeAttributableToShareholdersOfEsgInc.
178828 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25899468 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25899468 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001883835
CY2024Q3 ESGH Note Receivable Noncurrent
NoteReceivableNoncurrent
usd
CY2024Q3 ESGH Payable To Related Party Current
PayableToRelatedPartyCurrent
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Inventory Write Down
InventoryWriteDown
usd
ESGH Increase Decrease In Value Added Tax Receivable
IncreaseDecreaseInValueAddedTaxReceivable
usd
us-gaap Payments To Acquire And Develop Real Estate
PaymentsToAcquireAndDevelopRealEstate
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Loans
ProceedsFromLoans
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
usd
CY2023Q3 us-gaap Inventory Write Down
InventoryWriteDown
usd
us-gaap Inventory Write Down
InventoryWriteDown
usd
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
usd
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
dei Entity Address Address Line1
EntityAddressAddressLine1
523 School House Rd.
dei Entity Address City Or Town
EntityAddressCityOrTown
Kennett Square
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19348
dei City Area Code
CityAreaCode
267
dei Local Phone Number
LocalPhoneNumber
467-5871
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25899468 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
444835 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
342342 usd
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
210526 usd
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
79221 usd
CY2024Q3 us-gaap Supplies
Supplies
1208222 usd
CY2023Q4 us-gaap Supplies
Supplies
166010 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
1869777 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1651376 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
3733360 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2238949 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17948708 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18694969 usd
CY2024Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
3068514 usd
CY2023Q4 us-gaap Liabilities
Liabilities
13476073 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1708434 usd
us-gaap Revenues
Revenues
7122611 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
457306 usd
CY2024Q3 us-gaap Selling Expense
SellingExpense
2292 usd
CY2023Q3 us-gaap Selling Expense
SellingExpense
1263 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
127150 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
125380 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
-62553 usd
us-gaap Interest Expense
InterestExpense
406985 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26804 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-562011 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25899468 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25899468 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25899468 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25899468 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25899468 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25899468 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12797579 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-785488 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest
-214144 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11797947 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
104323 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest
-10779 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11891491 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3521 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest
217387 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12105357 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13567729 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-182448 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest
57782 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13443063 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
81161 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest
-555534 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12968690 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
74483 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest
-256423 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12786750 usd
us-gaap Profit Loss
ProfitLoss
-684686 usd
us-gaap Profit Loss
ProfitLoss
-26804 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1362759 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1092743 usd
us-gaap Inventory Write Down
InventoryWriteDown
201480 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
131305 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
140022 usd
ESGH Increase Decrease In Advance To Suppliers
IncreaseDecreaseInAdvanceToSuppliers
1042212 usd
ESGH Increase Decrease In Advance To Suppliers
IncreaseDecreaseInAdvanceToSuppliers
618092 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
218401 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-459850 usd
ESGH Increase Decrease In Value Added Tax Receivable
IncreaseDecreaseInValueAddedTaxReceivable
-168859 usd
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-41848 usd
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-17010 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1281062 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
274887 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
-30000 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
8689 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
436811 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-33776 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-97493 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-59569 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
951005 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
974916 usd
us-gaap Payments To Acquire And Develop Real Estate
PaymentsToAcquireAndDevelopRealEstate
385337 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-385337 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
427460 usd
us-gaap Payments For Loans
PaymentsForLoans
470206 usd
us-gaap Payments For Loans
PaymentsForLoans
710969 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-42746 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-710969 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-420429 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-305480 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
102493 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41533 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
342342 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
206621 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
444835 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165088 usd
us-gaap Interest Paid Net
InterestPaidNet
406985 usd
us-gaap Interest Paid Net
InterestPaidNet
287134 usd
CY2023Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
10432800 shares
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zIThJOPSOP1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86C_zIMLcehoBZWc">Use of estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In preparing the consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the dates of consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting year. Significant items subject to such estimates and assumptions include allowance for doubtful accounts, advances to suppliers, valuation of inventories, useful lives of property, plant, and equipment, and intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2024Q3 us-gaap Advances To Affiliate
AdvancesToAffiliate
1208222 usd
CY2023Q4 us-gaap Advances To Affiliate
AdvancesToAffiliate
166010 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zVoacXdeBAOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zqRo08z56lh5">Customer concentration</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zKGtA778cUne" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zgINDVGMV5H5" style="display: none">Schedule customer concentration</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended September 30, (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30, (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Customer A</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zOIn7Euf1fdh" title="Customer concentration">25</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zhrZhqJoR9Yd" title="Customer concentration">21</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_ztSnYz8Garl8" title="Customer concentration">17</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zm5TqwCldL0b" title="Customer concentration">20</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_ztWruzuNMCwk" title="Customer concentration">37</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zQoTwy6HqSpb" title="Customer concentration"><span style="-sec-ix-hidden: xdx2ixbrl0636">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zCGz6My3Phzg" title="Customer concentration">20</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zQghVg1Rovae" title="Customer concentration"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zL3qGidwvIXl" title="Customer concentration">19</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_ze47qIHpUmJ8" title="Customer concentration"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z2i53BgcziZe" title="Customer concentration">20</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zB66hOukLQL9" title="Customer concentration"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zwJgzwFjsDj6" title="Customer concentration">16</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zR6cYds8Jpk6" title="Customer concentration"><span style="-sec-ix-hidden: xdx2ixbrl0652">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zy1ZyvGeR1u" title="Customer concentration">15</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerDMember_zJ1wqdidNQEe" title="Customer concentration"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer E</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zVT92CrYNWT2" title="Customer concentration"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zAy15Pb5sDCa" title="Customer concentration">43</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zpxVCtBaWOT3" title="Customer concentration"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerEMember_zKUDvCPrkDB2" title="Customer concentration">42</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A7_zlDq6UamxEXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<p id="xdx_842_eus-gaap--RevenueRecognitionDeferredRevenue_zPEsuKXkyJcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_z17nS1JHDuzg">Deferred income</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government grants (sometimes referred to as subsidies, subventions, etc.) are as assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity. Deferred income consists primarily of government grants related to depreciable assets. Government grants received relating to depreciable assets are recorded as deferred income and recognized in over the life of the related assets. Company records income when receiving a grant which constitutes compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs. As of September 30, 2024 and December 31, 2023, deferred income was $<span id="xdx_902_eus-gaap--DeferredIncome_c20240930_pp0p0" title="Deferred income">1,271,088</span> and $<span id="xdx_904_eus-gaap--DeferredIncome_c20231231_pp0p0" title="Deferred income">1,355,552</span>, respectively. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q3 us-gaap Deferred Income
DeferredIncome
1271088 usd
CY2023Q4 us-gaap Deferred Income
DeferredIncome
1355552 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
144582 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
152839 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
404366 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
457306 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-26218 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
28829 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-201063 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
13337 usd
CY2024Q3 ESGH Negative Working Capital
NegativeWorkingCapital
9957879 usd
CY2024Q3 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
1708434 usd
CY2023Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
1224811 usd
us-gaap Profit Loss
ProfitLoss
-684686 usd
us-gaap Profit Loss
ProfitLoss
-26804 usd
CY2024Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
106267 usd
CY2024Q3 us-gaap Other Receivables
OtherReceivables
104259 usd
CY2023Q4 us-gaap Other Receivables
OtherReceivables
79221 usd
CY2024Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
210526 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
79221 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25560931 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24895726 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7612223 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6200757 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17948708 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18694969 usd
CY2024Q3 us-gaap Depreciation
Depreciation
444538 usd
CY2023Q3 us-gaap Depreciation
Depreciation
364247 usd
us-gaap Depreciation
Depreciation
1312054 usd
us-gaap Depreciation
Depreciation
1040765 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1733520 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1516634 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
91342 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
90326 usd
CY2024Q3 ESGH Inventory Work In Process Growing Mushrooms
InventoryWorkInProcessGrowingMushrooms
44915 usd
CY2023Q4 ESGH Inventory Work In Process Growing Mushrooms
InventoryWorkInProcessGrowingMushrooms
44416 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
1869777 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1651376 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3380313 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3342733 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-311799 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-256827 usd
CY2024Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
3068514 usd
CY2023Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
3085906 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18288 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17594 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
50705 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
51978 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
73151 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
73151 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
73151 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
73151 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
73151 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2702759 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3068514 usd
CY2024Q3 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
6939101 usd
CY2023Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
6904228 usd
CY2024Q3 us-gaap Customer Advances Current
CustomerAdvancesCurrent
120674 usd
CY2023Q4 us-gaap Customer Advances Current
CustomerAdvancesCurrent
63867 usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
105099 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
181950 usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
13951 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
16131 usd
CY2024Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
2509859 usd
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
2050824 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2749583 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2312772 usd
CY2024Q3 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
2380839 usd
CY2023Q4 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
2211980 usd
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Rate
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationRate
1 pure
us-gaap Payments Of Dividends
PaymentsOfDividends
2151383 usd
ESGH Monthly Payment
MonthlyPayment
25612 usd
CY2024Q3 us-gaap Deferred Income Revenue Recognized
DeferredIncomeRevenueRecognized
29084 usd
CY2023Q3 us-gaap Deferred Income Revenue Recognized
DeferredIncomeRevenueRecognized
29652 usd
us-gaap Deferred Income Revenue Recognized
DeferredIncomeRevenueRecognized
185875 usd
us-gaap Deferred Income Revenue Recognized
DeferredIncomeRevenueRecognized
133180 usd
CY2024Q3 us-gaap Inventory Write Down
InventoryWriteDown
29264 usd
us-gaap Inventory Write Down
InventoryWriteDown
201480 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-180 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29652 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15605 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
133180 usd
CY2024Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
584785 usd
CY2023Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
563375 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1131025 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1647017 usd
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.04 pure
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.04 pure
CY2024Q3 ESGH Effect Of Income Tax Exemption On Certain Income
EffectOfIncomeTaxExemptionOnCertainIncome
-1.41 pure
CY2023Q3 ESGH Effect Of Income Tax Exemption On Certain Income
EffectOfIncomeTaxExemptionOnCertainIncome
-1.70 pure
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.66 pure
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.95 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.04 pure
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.04 pure
ESGH Effect Of Income Tax Exemption On Certain Income
EffectOfIncomeTaxExemptionOnCertainIncome
-0.29 pure
ESGH Effect Of Income Tax Exemption On Certain Income
EffectOfIncomeTaxExemptionOnCertainIncome
-12.06 pure
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.54 pure
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
12.31 pure
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-374704 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-371072 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
374704 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
371072 usd
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2905848 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2531144 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2905848 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2531144 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25899468 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25899468 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25899468 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25899468 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001520138-24-000421-index-headers.html Edgar Link pending
0001520138-24-000421-index.html Edgar Link pending
0001520138-24-000421.txt Edgar Link pending
0001520138-24-000421-xbrl.zip Edgar Link pending
esgh-20240930.xsd Edgar Link pending
esgh-20240930_10q.htm Edgar Link pending
esgh-20240930_ex31z1.htm Edgar Link pending
esgh-20240930_ex32z1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
esgh-20240930_cal.xml Edgar Link unprocessable
esgh-20240930_def.xml Edgar Link unprocessable
esgh-20240930_10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
esgh-20240930_pre.xml Edgar Link unprocessable
esgh-20240930_lab.xml Edgar Link unprocessable